On June 3, Kelun-Biotech Biopharmaceutical fell 3.17% in regular trading, trading at 387.2 HKD/share, with trading volume of approximately 70.8 million HKD.

On the news front, the decline extends a multi-day selloff driven by the comprehensive performance slowdown across the Kelun group and chairman Liu Gexin's consecutive stake reduction. HKEX filings revealed Liu sold approximately 257,300 shares between May 26-28, intensifying market concerns. Fundamentally, while Kelun-Biotech reported revenue growth of 6.5% to 2.058 billion yuan, net losses widened to 382 million yuan from 267 million yuan a year earlier, primarily due to sharply reduced licensing and milestone income alongside elevated R&D expenses of approximately 1.32 billion yuan. Parent company Kelun Pharmaceutical also saw net profit plunge 42% year-over-year. The broader biotechnology sector traded lower, with AKESO down 3.94%, 3SBIO down 3.68%, INNOVENT BIO down 3.04%, and BEIGENE down 2.67%, adding sector-wide headwinds.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)